Non-Hodgkin Lymphoma by Clinical Course

Non-Hodgkin Lymphoma by Clinical Course — Trials · CancerIndex

Clinical trials

Registered studies

1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 173
Ph III recruiting: 8
Growth YoY: +32.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (209)

clinicaltrialsPublishedShowing 101–150 of 1,200 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06340737	AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	recruiting	Phase 1	148	Stanford UniversityOTHER	1	Aug 12, 2026	clinicaltrials
NCT06792825	HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL	recruiting	Phase 2	65	Masonic Cancer Center, University of MinnesotaOTHER	1	Aug 12, 2026	clinicaltrials